Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen s Strong Q4 Earnings Report Tops Most-Read GenomeWeb News Stories Last Week

NEW YORK, March 6 (GenomeWeb News) - What are GenomeWeb News subscribers reading? Below are the five most-read articles for the five-day period ended Friday, March 3.

 

1. Invitrogen's Q4 Revenues Grow 24 Percent as Profit Jumps 63 Percent (from Feb. 28)

2. Invitrogen Shares Climb 5.4 Percent on Strong Q4, Flu Deal, Stock Upgrade (from March 1)

3. ABI Wraps Up $273M Acquisition of Ambion's RNA Business (from March 2)

4. Liotta and Petricoin, Italian Health Agency to Identify Proteomic Biomarkers, Drug Targets for Cancer (from March 2)

5. Investment Community Starts to Weigh in on Solexa. Should 454 Worry? (from Feb. 28)

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.